| |
 |
|
|
|
|
| Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent |
|
|
|
Tokyo, Jan 9, 2013 (JCN) - Chugai Pharmaceutical has granted Debiopharm Group an exclusive license to develop and commercialise FF284 in all countries worldwide including Japan. FF284, called Debio 1347 by Debiopharm, was discovered by Chugai and is about to start clinical development in oncology.
Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialise a companion diagnostic for FF284. According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study.
Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent
(Jan 9, 2013)
|
|
|
Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial
(Dec 16, 2008)
|
|
|
DATA from Overseas Phase III Trial of "Actemra" a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, Demonstrates Efficacy in Preventing Structural Joint Damage in Rheumatoid Arthritis Patients
(Oct 27, 2008)
|
|
|
Roche to Raise Chugai Pharm Stake to 59.9 Percent
(May 23, 2008)
|
|
|
Chugai Pharmaceutical Announcement of Supplemental Approval of Indication of Sigmart(R) Injection, a Treatment Drug for Unstable Angina Pectoris
(Oct 23, 2007)
|
|
|
Chugai Pharmaceutical Announcement Anti-Cancer Agent Tarceva(R) Tablet Approved in Japan
(Oct 22, 2007)
|
|
|
Chugai to Conduct Additional Clinical Trial for Additional Indication of the Recombinant Human Erythropoietin "Epogin(R) Injection" for Treatment of Chemotherapy-Induced Anemia
(Sept 27, 2007)
|
|
|
Teijin and Chugai Enter Agreement to Co-develop Ipsen's Anti-diabetic Medicine in Japan
(Aug 23, 2007)
|
|
|
Chugai Introduces New System to Assist its Medical Representatives to Raise Children
(May 7, 2007)
|
|
|
Overseas Co-Promotion of Actemra(R), a Treatment for Rheumatoid Arthritis
(May 7, 2007)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
|
|
|
|
